MedTrace Logo

Short-term Supplementation, Bone Turnover and Antioxidant Status in Menopause

NCT03672513 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 78

Last updated 2018-09-14

No results posted yet for this study

Summary

This is a 8-week, double-blinded, placebo-controlled, randomized intervention trial to investigate the effects of Mg and Zn supplementation on antioxidant status and bone hormonal parameters. Participants were randomly assigned to one of three treatment groups: Placebo group (PbG: 25 women); Magnesium Group - 500 mg/day of Mg (MgG: 27 women); Zinc Group - 50 mg/day of Zn (ZnG: 26 women).

Conditions

  • Menopause
  • Nutritional Intervention
  • Bone Diseases

Interventions

DIETARY_SUPPLEMENT

Placebo Comparator

Oral administration of 1 daily capsule containing lactose

DIETARY_SUPPLEMENT

Zinc Supplement

Oral administration of 1 daily capsule containing 50 mg/day of Zn

DIETARY_SUPPLEMENT

Magnesium supplement

Oral administration of 1 daily capsule containing 500 mg/day of Magnesium

Sponsors & Collaborators

  • Universidad de Granada

    lead OTHER

Principal Investigators

  • Elena Planells, PhD · Universidad de Granada

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
44 Years
Max Age
76 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-09-08
Primary Completion
2017-11-01
Completion
2018-09-08

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03672513 on ClinicalTrials.gov